Pharmaceutical company Takeda Ireland has today announced a €36m investment in its Grange Castle facility in Dublin, which will create about 100 new jobs over the next three years.

Takeda said the investment will support the expansion of its cell therapy production facility, which is the first of its kind in Ireland. 

Following the expansion, the company said the Grange Castle facility will play an important role in supplying European, US and Canadian markets with a cell therapy treatment option for patients.

Thomas Wozniewski, Takeda's Global Manufacturing & Supply Officer, said the investment to expand its cell therapy production facility highlights the importance of cell therapy for the company. 

"The expansion of the cell therapy manufacturing line in Grange Castle will help us to serve more patients worldwide, and it underlines our commitment to Ireland as a key country. With its advanced use of digital technologies, the cell therapy manufacturing lines in Grange Castle are a testimony to our innovation capabilities," he added. 

Paul Keogh, Grange Castle Site Head, said that since beginning operations in 2007, the Grange Castle site has grown from strength to strength thanks to a great team and strong investment in our people and technology. 

"The investment announced today further highlights Grange Castle as a trusted manufacturing site in the network and that's something we are very proud of," he added.

Tánaiste and Minister for Enterprise, Trade and Employment, Leo Varadkar said the country's highly skilled workforce is just one of the reasons why Ireland is recognised as a global hub for biopharmaceutical companies like Takeda.

The chief executive of IDA Ireland, Martin Shanahan, said that Takeda's continued investment at its Grange Castle facility and the creation of 100 additional highly skilled roles demonstrates a huge vote of confidence in Ireland and our strong value proposition. 

"Cell therapy is a core pillar in the emerging field of Advanced Therapy Medicinal Products (ATMPs), widely considered as the next generation of pharmaceutical therapies," Mr Shanahan said. 

"These products require highly innovate approaches to manufacturing and offer unparalleled opportunities in the treatment of disease. This investment is an important endorsement of Ireland's reputation as a global location of excellence for next generation biopharmaceutical products," the IDA CEO added.